Ethmoiditis-associated apex syndrome may result in temporary blindness after allo-SCT

被引：0
|
作者：
Olsson, R. [1 ]
Juto, J-E [2 ]
Mattsson, J. [1 ]
机构：
[1] Karolinska Univ Hosp, Karolinska Inst, Ctr Allogene Stem Cell Transplantat, Huddinge, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Otorhinolaryngol, Huddinge, Sweden
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 44卷 / 12期
关键词：
STEM-CELL TRANSPLANTATION; FUNGAL-INFECTIONS; RECIPIENTS; SINUSITIS;
D O I：
10.1038/bmt.2009.85
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：825 / 826
页数：2
相关论文
共 42 条
  • [31] CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
    F Rosenow
    A Berkemeier
    U Krug
    C Müller-Tidow
    J Gerss
    G Silling
    C Groth
    P Wieacker
    N Bogdanova
    R Mesters
    T Büchner
    J Kienast
    W E Berdel
    M Stelljes
    Bone Marrow Transplantation, 2013, 48 : 1070 - 1076
  • [32] CD34+ lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
    Rosenow, F.
    Berkemeier, A.
    Krug, U.
    Mueller-Tidow, C.
    Gerss, J.
    Silling, G.
    Groth, C.
    Wieacker, P.
    Bogdanova, N.
    Mesters, R.
    Buechner, T.
    Kienast, J.
    Berdel, W. E.
    Stelljes, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 (08) : 1070 - 1076
  • [33] Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Liu, Hongtao
    Artz, Andrew
    Larson, Richard A.
    Kosuri, Satyajit
    Stock, Wendy
    Bishop, Michael R.
    BLOOD, 2017, 130
  • [34] A novel predictor for response to therapy of Epstein-Barr virus (ebv) associated lymphoproliferative disease after allogeneic stem cell transplantation (ALLO-SCT).
    Christine, B
    Kortmann, K
    Schäfer, M
    Sester, U
    Kaul, H
    Pees, H
    Mueller-Lantzsch, N
    TRANSPLANTATION, 2001, 71 (01) : S1 - S1
  • [35] Relapse after allo-SCT is associated with high PD-1 and TIGIT expression on tumor-reactive CD8+T cells
    Hutten, T.
    Norde, W.
    Woestenenk, R.
    Maas, F.
    Kester, M.
    Falkenburg, F.
    Schaap, N.
    Jansen, J.
    Dolstra, H.
    Hobo, W.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S162 - S162
  • [36] CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
    Kapp, M.
    Stevanovic, S.
    Fick, K.
    Tan, S. M.
    Loeffler, J.
    Opitz, A.
    Tonn, T.
    Stuhler, G.
    Einsele, H.
    Grigoleit, G. U.
    BONE MARROW TRANSPLANTATION, 2009, 43 (05) : 399 - 410
  • [37] CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT
    M Kapp
    S Stevanović
    K Fick
    S M Tan
    J Loeffler
    A Opitz
    T Tonn
    G Stuhler
    H Einsele
    G U Grigoleit
    Bone Marrow Transplantation, 2009, 43 : 399 - 410
  • [38] Weekly high-dose cidofovir is an effective treatment for symptomatic BK virus (BKV)-associated hemorrhagic cystitis (HC) after allogeneic stem cell transplantation (Allo-SCT).
    Baltathakis, Ioannis
    Michael, Michael
    Grispou, Eirini
    Kourti, Georgia
    Bouzani, Maria
    Anagnostopoulou, Maria
    Apostolidis, John
    Karakassis, Dimitrios
    Harhalakis, Nicholas
    Paniara, Olga
    Nikiforakis, Emmanuel
    BLOOD, 2006, 108 (11) : 418B - 418B
  • [39] Maintenance therapy with 5-azacytidine (5-AC) after allogeneic stem cell transplantation (allo-SCT) for acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS): A dose and schedule finding study.
    Soriano, Andres O.
    Champlin, Richard
    McCormick, Gloria
    Giralt, Sergio
    Thall, Peter
    Komanduri, Krishna
    Qazilbash, Muzaffar
    Garcia-Manero, Guillermo
    De Lima, Marcos
    BLOOD, 2006, 108 (11) : 1048A - 1048A
  • [40] Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate
    Santoro, Armando
    Castagna, Luca
    Magagnoli, Massimo
    Bramanti, Stefania
    Mariotti, Jacopo
    Mazza, Rita
    Morello, Lucia
    Ricci, Francesca
    Sarina, Barbara
    De Philippis, Chiara
    Sica, Simona
    Rodari, Marcello
    Sollini, Martina
    Kirienko, Margarita
    Giordano, Laura
    Chiti, Arturo
    Corradini, Paolo
    Carlo-Stella, Carmelo
    BLOOD, 2018, 132
12345